NASDAQ:PPBT

Purple Biotech Competitors

$3.97

+0.06 (+1.53 %)

(As of 05/7/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.94

▼

$4.09

50-Day Range

$3.83

▼

$4.66

52-Week Range

$3.60

▼

$14.40

Volume122,200 shs

Average Volume739,855 shs

Market Capitalization$69.52 million

P/E RatioN/A

Dividend YieldN/A

Beta2.33

Purple Biotech (NASDAQ:PPBT) Vs. ONCT, CTXR, KMDA, ABUS, KZR, and TRVN

Should you be buying PPBT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Purple Biotech, including Oncternal Therapeutics (ONCT), Citius Pharmaceuticals (CTXR), Kamada (KMDA), Arbutus Biopharma (ABUS), Kezar Life Sciences (KZR), and Trevena (TRVN).

Purple Biotech vs. Oncternal Therapeutics Stock

Oncternal Therapeutics (NASDAQ:ONCT) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Oncternal Therapeutics and Purple Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncternal Therapeutics	0	0	5	0	3.00
Purple Biotech	0	0	1	0	3.00

Oncternal Therapeutics currently has a consensus price target of $15.20, suggesting a potential upside of 173.38%. Given Purple Biotech's higher probable upside, analysts clearly believe Purple Biotech is more favorable than Oncternal Therapeutics.

Institutional & Insider Ownership

10.8% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 2.7% of Purple Biotech shares are held by institutional investors. 10.9% of Oncternal Therapeutics shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Oncternal Therapeutics and Purple Biotech's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncternal Therapeutics	$2.42 million	113.41	$-34,190,000.00	($1.56)	-3.56
Purple Biotech	$1 million	69.52	$-5,850,000.00	($3.00)	-1.32

Purple Biotech has lower revenue, but higher earnings than Oncternal Therapeutics. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Oncternal Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500.

Profitability

This table compares Oncternal Therapeutics and Purple Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncternal Therapeutics	-746.10%	-150.58%	-91.87%
Purple Biotech	N/A	N/A	N/A

Summary

Purple Biotech beats Oncternal Therapeutics on 7 of the 13 factors compared between the two stocks.

Purple Biotech vs. Citius Pharmaceuticals Stock

Purple Biotech (NASDAQ:PPBT) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.

Profitability

This table compares Purple Biotech and Citius Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	N/A	N/A
Citius Pharmaceuticals	N/A	-62.67%	-48.27%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Purple Biotech and Citius Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	0	0	1	0	3.00
Citius Pharmaceuticals	0	0	2	0	3.00

Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 130.41%. Given Purple Biotech's higher probable upside, research analysts plainly believe Purple Biotech is more favorable than Citius Pharmaceuticals.

Risk and Volatility

Purple Biotech has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.

Valuation and Earnings

This table compares Purple Biotech and Citius Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	$1 million	69.52	$-5,850,000.00	($3.00)	-1.32
Citius Pharmaceuticals	N/A	N/A	$-17,550,000.00	N/A	N/A

Purple Biotech has higher revenue and earnings than Citius Pharmaceuticals.

Institutional & Insider Ownership

2.7% of Purple Biotech shares are held by institutional investors. Comparatively, 1.9% of Citius Pharmaceuticals shares are held by institutional investors. 3.0% of Purple Biotech shares are held by insiders. Comparatively, 33.9% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Purple Biotech beats Citius Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Purple Biotech vs. Kamada Stock

Purple Biotech (NASDAQ:PPBT) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Purple Biotech and Kamada's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	N/A	N/A
Kamada	15.60%	12.89%	10.66%

Analyst Recommendations

This is a summary of recent ratings for Purple Biotech and Kamada, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	0	0	1	0	3.00
Kamada	0	0	2	0	3.00

Kamada has a consensus target price of $11.00, suggesting a potential upside of 79.74%. Given Purple Biotech's higher probable upside, equities analysts clearly believe Purple Biotech is more favorable than Kamada.

Risk and Volatility

Purple Biotech has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Earnings & Valuation

This table compares Purple Biotech and Kamada's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	$1 million	69.52	$-5,850,000.00	($3.00)	-1.32
Kamada	$127.19 million	2.14	$22.25 million	$0.55	11.13

Kamada has higher revenue and earnings than Purple Biotech. Purple Biotech is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

2.7% of Purple Biotech shares are owned by institutional investors. Comparatively, 14.3% of Kamada shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Kamada beats Purple Biotech on 9 of the 13 factors compared between the two stocks.

Purple Biotech vs. Arbutus Biopharma Stock

Purple Biotech (NASDAQ:PPBT) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Purple Biotech and Arbutus Biopharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	N/A	N/A
Arbutus Biopharma	-1,163.48%	N/A	-59.66%

Institutional and Insider Ownership

2.7% of Purple Biotech shares are owned by institutional investors. Comparatively, 28.4% of Arbutus Biopharma shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 6.7% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Purple Biotech has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 3.15, meaning that its stock price is 215% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Purple Biotech and Arbutus Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	0	0	1	0	3.00
Arbutus Biopharma	0	2	5	0	2.71

Arbutus Biopharma has a consensus target price of $6.50, suggesting a potential upside of 131.32%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Purple Biotech is more favorable than Arbutus Biopharma.

Earnings & Valuation

This table compares Purple Biotech and Arbutus Biopharma's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	$1 million	69.52	$-5,850,000.00	($3.00)	-1.32
Arbutus Biopharma	$6.01 million	45.07	$-153,720,000.00	($1.62)	-1.73

Purple Biotech has higher earnings, but lower revenue than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Purple Biotech beats Arbutus Biopharma on 7 of the 13 factors compared between the two stocks.

Purple Biotech vs. Kezar Life Sciences Stock

Purple Biotech (NASDAQ:PPBT) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Purple Biotech and Kezar Life Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	N/A	N/A
Kezar Life Sciences	N/A	-31.71%	-29.17%

Institutional & Insider Ownership

2.7% of Purple Biotech shares are owned by institutional investors. Comparatively, 49.5% of Kezar Life Sciences shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 7.6% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Purple Biotech has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Purple Biotech and Kezar Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	0	0	1	0	3.00
Kezar Life Sciences	0	1	2	0	2.67

Kezar Life Sciences has a consensus target price of $15.00, suggesting a potential upside of 167.86%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities research analysts clearly believe Purple Biotech is more favorable than Kezar Life Sciences.

Earnings and Valuation

This table compares Purple Biotech and Kezar Life Sciences' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	$1 million	69.52	$-5,850,000.00	($3.00)	-1.32
Kezar Life Sciences	N/A	N/A	$-35,090,000.00	($1.84)	-3.04

Purple Biotech has higher revenue and earnings than Kezar Life Sciences. Kezar Life Sciences is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Purple Biotech beats Kezar Life Sciences on 8 of the 12 factors compared between the two stocks.

Purple Biotech vs. Trevena Stock

Purple Biotech (NASDAQ:PPBT) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Purple Biotech and Trevena's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	N/A	N/A
Trevena	N/A	-42.49%	-34.83%

Earnings and Valuation

This table compares Purple Biotech and Trevena's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	$1 million	69.52	$-5,850,000.00	($3.00)	-1.32
Trevena	$30,000.00	8,762.55	$-24,870,000.00	($0.27)	-6.04

Purple Biotech has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

2.7% of Purple Biotech shares are owned by institutional investors. Comparatively, 11.6% of Trevena shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 5.2% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Purple Biotech and Trevena, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	0	0	1	0	3.00
Trevena	0	1	3	0	2.75

Trevena has a consensus target price of $5.00, suggesting a potential upside of 206.75%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities research analysts clearly believe Purple Biotech is more favorable than Trevena.

Volatility and Risk

Purple Biotech has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500. Comparatively, Trevena has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500.

Summary

Purple Biotech beats Trevena on 7 of the 13 factors compared between the two stocks.